HIHO 36% v12,9M c3.60 f3,8M preMH8.28 HODnear $5 then

New Post Public Reply Private Reply Replies (0) Message Board
znewcar1
246

HIHO 36% v12,9M c3.60 f3,8M preMH8.28 HODnear $5 then fell shortly after bell.
SEC Filings3:00 AM
Statement of changes in beneficial ownership of securities - Form 4
Fri Jul 31st, 2020
Business Wire4:00 PM
Highway Holdings Announces Delay in Reporting Fiscal 2020 Results Due to Coronavirus
SEC Filings3:00 AM
Notification of inability to timely file Form 20-F - Form NT 20-F
Thu Jul 30th, 2020
SEC Filings3:00 AM
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 - Form 6-K
Thu Jul 2nd, 2020
Business Wire8:30 AM
Highway Holdings Announces Timing of Fiscal 2020 Reporting and Annual Meeting of Shareholders
SEC Filings3:00 AM
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 - Form 6-K
Wed Apr 1st, 2020
Business Wire8:00 AM
Highway Holdings Appoints New Directors
SEC Filings3:00 AM
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 - Form 6-K
Mon Mar 2nd, 2020
SEC Filings3:00 AM
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 - Form 6-K
Mon Feb 24th, 2020
Business Wire8:30 AM
Highway Holdings Limited Declares Cash Dividend


Highway Holdings Ltd. (HIHO) Stock Research Links

HIHO Board Company Profile Buy Rating Time & Sales News Filings Financials
The majority of my post are the top 20% gainer! To decode them its (ticker ID, % Changed, Volume, Close price and Float) I typically put V,C&F as a prefix to that number and use K, M and B as a suffix (Kilo, Million & Billion) for volume and float. I may also use S for Support and R for Resistance.

I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 24

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 33

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 28

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 18

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 37

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 46

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 30

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Gene-Editing Therapy CS-121 Revolutionizes Hyperlipidemia Treatment

Updated Category News Views 232

Transformative Progress in Gene-Editing Therapies CorrectSequence Therapeutics Co., Ltd. is at the forefront of biotechnology innovation with its promising gene-editing therapy, CS-121, designed to tackle chylomicronemia and hypertriglyceridemia. This breakthrough comes as an exciting advancement in the medical field, particularly for patients suffering from severe lipid...

Continue Reading
Blue Ridge Partners Showcases Expertise at PEI Forum Europe

Updated Category News Views 211

Blue Ridge Partners Takes Center Stage at Key Forum Blue Ridge Partners, a leading global management consultancy, will serve as the Knowledge Partner for a significant upcoming event in the private equity sector. The firm is excited to announce its role in the 2025 PEI Operating Partners Forum Europe, taking place in May. Over a decade of collaboration as the Knowledge...

Continue Reading
Alger Russell Innovation Index Q4 2025 Rebalancing Insights

Updated Category News Views 81

Alger Russell Innovation Index Changes for Q4 2025 Fred Alger Management, LLC, a notable growth equity investment manager, has announced significant updates to the Alger Russell Innovation Index. This announcement concerns the quarterly rebalancing that will take place after the trading session concludes. These changes reflect the ever-evolving landscape of investment...

Continue Reading
Partners Value Split Corp. Announces Redemption of Shares

Updated Category News Views 205

Partners Value Split Corp. to Redeem Class AA Preferred Shares Recently, Partners Value Split Corp. (the “Company”) shared exciting news regarding its Class AA Preferred Shares, Series 9. This announcement indicates the Company’s intention to redeem all of its outstanding 5,996,800 Preferred Shares, Series 9 for cash, in accordance with the established terms....

Continue Reading
Pagos' MCP Server: The Future of Payment Data Access?

Updated Category News Views 160

Pagos unveiled a significant upgrade to its Model Context Protocol (MCP) Server on February 17, 2026. This expansion aims to revolutionize how merchants access and analyze their verified payments data directly via AI chat agents like ChatGPT and Claude. Traders in the fintech space are already sizing up this move, pondering whether it marks a genuine leap forward or just...

Continue Reading